ArticleInternational journal of general medicine2025
Application Value of Novel Inflammatory Indicators in Response to Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ursodeoxycholic Acid Alleviates DSS/AOM-Induced Colorectal Cancer in Mice by Inhibiting PI3K/Akt/mTOR Signaling Pathway.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the application value of novel inflammation indicators such as the lymphocyte/monocyte ratio (LMR), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) in patients with primary biliary cholangitis (PBC) undergoing ursodeoxycholic acid (UDCA) treatment. We plan to further seek simple and convenient methods to assess the response of patients to UDCA treatment. Methods: We recorded routine blood tests, liver function, and vitamin D (VD) levels of PBC patients and healthy controls visiting the hospital between October 2022 and October 2023. LMR, NLR, and PLR were calculated, and differences between the two groups were analyzed. PBC patients were divided into good response and poor response groups according to the Paris I criteria, and differences in laboratory tests between the two groups were analyzed. The predictive value of novel inflammation indicators in UDCA treatment response was further analyzed using ROC analysis. Results: LMR and VD levels were significantly lower in the PBC group compared to the control group ( Conclusion: Low LMR and high NLR may indicate poor treatment response. And PLR also have certain predictive values for treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.